Assignee
IRONWOOD PHARMACEUTICALS INC
US·21 granted patents·102 pending applications·247 citations·filing 2005–2024
Top patents by PatentIndex Score
123 records- 0196US7494979B2Method for treating congestive heart failure and other disordersIRONWOOD PHARMACEUTICALS INC·Filed 2005·Granted Feb 24, 2009·38 cites·14 claims
- 0295US7910546B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2008·Granted Mar 22, 2011·29 cites·28 claims
- 0395US7745409B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2007·Granted Jun 29, 2010·29 cites·7 claims
- 0495US7704947B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2007·Granted Apr 27, 2010·29 cites·16 claims
- 0594US9586937B2sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2016·Granted Mar 7, 2017·13 cites·2 claims
- 0693US9481689B2sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2014·Granted Nov 1, 2016·16 cites·2 claims
- 0793US7772188B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2005·Granted Aug 10, 2010·31 cites·10 claims
- 0892US9840536B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2015·Granted Dec 12, 2017·8 cites·4 claims
- 0991US10183021B2sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2016·Granted Jan 22, 2019·8 cites·9 claims
- 1091US9725453B2Imidazotriazinone compoundsIRONWOOD PHARMACEUTICALS INC·Filed 2014·Granted Aug 8, 2017·7 cites·2 claims
- 1191US9139564B22-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2012·Granted Sep 22, 2015·15 cites·6 claims
- 1287US9309235B2SGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2013·Granted Apr 12, 2016·12 cites·25 claims
- 1385US2023346881A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1485US2024075094A1Low-Dose Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1585US2023340025A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1684US2023248758A1Methods of treating upper gastrointestinal disorders in ppi refractory gerdIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1783US2023310329A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1883US2024115656A1Treatment of Constipation-Predominant Irritable Bowel SyndromeIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1981US8946158B2Treatments of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2013·Granted Feb 3, 2015·5 cites·35 claims
- 2081US2023263854A1Treatment of Constipation-Predominant Irritable Bowel SyndromeIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2180US10047095B2sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2015·Granted Aug 14, 2018·4 cites·26 claims
- 2279US2025073301A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2379US2022227812A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2479US2023272007A1Treatments for gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2579US2022233635A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2678US10675325B2Stable formulations of linaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Granted Jun 9, 2020·0 cites·18 claims
- 2778US2022125734A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2878US2022133777A1Methods of treating upper gastrointestinal disorders in ppi refractory gerdIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2976US2022031802A1Low-Dose Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3075US10702576B2Stable formulations of linaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Granted Jul 7, 2020·0 cites·20 claims
- 3175US2021388026A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3275US2021290554A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3375US2020113931A1Methods of treating upper gastrointestinal disorders in ppi refractory gerdIRONWOOD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3475US2023398173A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3575US2021290662A1Methods of treating upper gastrointestinal disorders in ppi refractory gerdIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3675US2011129433A1Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 3775US2022111001A1Treatment of Constipation-Predominant Irritable Bowel SyndromeIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3874US9540380B2Imidazotriazinone compoundsIRONWOOD PHARMACEUTICALS INC·Filed 2014·Granted Jan 10, 2017·1 cites·1 claims
- 3974US2022370367A1Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid SequestrantIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4073US2023142270A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4172US10618938B2Compositions for colon cleansing and the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2016·Granted Apr 14, 2020·1 cites·30 claims
- 4271US7960544B2Useful indole compoundsIRONWOOD PHARMACEUTICALS INC·Filed 2006·Granted Jun 14, 2011·1 cites·34 claims
- 4371US2022110876A1Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid SequestrantIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4471US2020283479A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4570US2022119452A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4670US2014287034A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4768US2020009216A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4868US2021267903A1Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid SequestrantIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4967US2022202725A1Modified or Targeted Release Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 5067US2024199697A1Compositions for Colon Cleansing and the Treatment of Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
Showing the top 50 of 123 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →